natgillin/translations-raw huggingface dataset:
Vectibix in combination with FOLFIRI has been investigated in a main study involving 1,186 patients who had been treated before, where Vectibix was compared with chemotherapy alone.
Zdravilo Vectibix so v kombinaciji s kemoterapijo FOLFIRI proučevali v glavni študiji, ki je zajela 1 186 bolnikov, ki so že bili zdravljeni, in ga primerjali s samostojno kemoterapijo.
Vectibix in combination with FOLFIRI has been investigated in a study involving 154 previously untreated patients which looked mainly at the percentage of patients who responded to treatment.
Zdravilo Vectibix so v kombinaciji s kemoterapijo FOLFIRI proučevali v študiji, ki je zajela 154 predhodno nezdravljenih bolnikov, opazovali pa so predvsem, kolikšen delež bolnikov se je odzval na zdravljenje.
Vectibix in combination with FOLFOX has been investigated in a main study involving 1,183 patients who had not been treated before for their metastatic cancer, where Vectibix was compared with chemotherapy alone.
Zdravilo Vectibix so v kombinaciji s kemoterapijo FOLFOX proučevali v glavni študiji, ki je zajela
Vectibix is a cancer medicine that contains the active substance panitumumab.
Vectibix je zdravilo, ki vsebuje zdravilno učinkovino panitumumab.
Vectibix is a colourless liquid that may contain visible particles and is supplied in a vial.
Zdravilo Vectibix je brezbarvna tekočina, ki lahko vsebuje vidne delce, in je na voljo v vialah.
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): in first-line in combination with FOLFOX or FOLFIRI. in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Zdravilo Vectibix je indicirano za zdravljenje odraslih bolnikov z metastatskim kolorektalnim rakom (mKRR) z divjim tipom RAS: v prvi liniji zdravljenja v kombinaciji s FOLFOX ali FOLFIRI. v drugi liniji zdravljenja v kombinaciji s FOLFIRI pri bolnikih, ki so v prvi liniji zdravljenja prejemali kemoterapijo, ki je vključevala fluoropirimidin (vendar ni vključevala irinotekana). kot monoterapija po neuspehu shem kemoterapije, ki so vključevale fluoropirimidin, oksaliplatin in irinotekan.
Vectibix is intended for single use only.
Zdravilo Vectibix je namenjeno za enkratno uporabo.
Vectibix is used alone or in combination with other anticancer medicines.
Zdravilo Vectibix se uporablja samostojno ali v kombinaciji z drugimi zdravili proti raku.
Vectibix is used in patients whose tumour cells contain the most common form (non-mutated or wild-type) of RAS.
Zdravilo Vectibix se uporablja pri bolnikih, katerih tumorske celice vsebujejo najpogostejšo obliko (nemutirani ali divji tip) gena, imenovanega „RAS“.
Vectibix is used to treat metastatic cancer of the colon or rectum.
Zdravilo Vectibix se uporablja za zdravljenje metastatskega raka kolona ali danke.
Vectibix must be administered as an intravenous infusion via an infusion pump, using a low protein binding 0.2 or 0.22 micrometre in-line filter, through a peripheral line or indwelling catheter.
Zdravilo Vectibix morate aplicirati v intravenski infuziji z infuzijsko črpalko in uporabo 0,2 ali 0,22 mikrometrskega linijskega filtra z majhno vezavo beljakovin, in sicer skozi periferen venski kanal ali stalni kateter.
Vectibix must not be used with oxaliplatin-containing chemotherapy in patients whose tumour contains the mutated RAS gene or for whom the RAS status is not known.
Zdravilo Vectibix se pri bolnikih, pri katerih ni bilo potrjeno, da njihovi tumorji vsebujejo mutirani gen RAS, ali pri katerih stanje gena RAS ni znano, ne sme uporabljati s kemoterapijo, ki vsebuje oksaliplatin.
Vectibix on its own has been investigated in a study involving a total of 463 patients whose disease had got worse during or after previous treatment that included a fluoropyrimidine, oxaliplatin and irinotecan.
Zdravilo Vectibix samostojno je bilo raziskano v študiji s 463 bolniki, pri katerih se je bolezen poslabšala med predhodnim zdravljenjem s fluoropirimidinom, oksaliplatinom in irinotekanom ali po njem.
Vectibix plus BSC
zdravilo Vectibix in BSC
Vectibix plus FOLFIRI
Vectibix in FOLFIRI (meseci)
Vectibix plus FOLFOX
Vectibix in FOLFOX
Vectibix should be diluted in sodium chloride 9 mg/mL (0.9%) solution for injection by healthcare professional using aseptic technique.
Zdravilo Vectibix mora razredčiti zdravstveni delavec; za razredčenje je treba uporabiti natrijev klorid 9 mg/ml (0,9 %) raztopino za injiciranje in upoštevati je treba aseptični postopek.
Vectibix should not be administered in combination with IFL chemotherapy or with bevacizumab- containing chemotherapy.
Zdravila Vectibix se ne sme uporabljati v kombinaciji s kemoterapijo IFL ali kemoterapijo, ki vključuje bevacizumab.
Vectibix treatment should be supervised by a physician experienced in the use of anti-cancer therapy.
Zdravljenje z zdravilom Vectibix mora nadzirati zdravnik z izkušnjami pri uporabi terapije proti raku.
Vectibix was originally given ‘conditional approval’ because there was more evidence to come about the medicine.
Zdravilo Vectibix je prvotno pridobilo „pogojno dovoljenje za promet“, ker je bilo pričakovanih še več dokazov o zdravilu.
Vectibix will be administered in a healthcare facility under the supervision of a doctor experienced in the use of anti-cancer medicines.
Zdravilo Vectibix boste dobili v zdravstveni ustanovi, pod nadzorstvom zdravnika, izkušenega z uporabo zdravil proti raku.
Vectormune ND contains as active substance live turkey herpesvirus (rHVT/ND) expressing the fusion protein of Newcaste diseases virus D-26 lentogenic strain.
Zdravilo Vectormune ND vsebuje zdravilno učinkovino, živi puranji virus herpesa (rHVT/ND), ki izraža fuzijski protein lentogenega seva virusa bolezni Newcastle D-26.
Vectormune ND is a vaccine containing turkey herpesvirus; a type of herpesvirus which is closely related to MD herpesvirus but does not cause disease in chickens.
Vectormune ND je cepivo, ki vsebuje puranji virus herpesa, tj. vrsto virusa herpesa, ki je tesno povezan z virusom herpesa pri Marekovi bolezni, vendar pri piščancih ne povzroča bolezni.
Vectormune ND is a veterinary vaccine used to protect chickens against Newcastle disease (ND) and Marek’s disease (MD).
Vectormune ND je cepivo za uporabo v veterinarski medicini, ki se uporablja za zaščito piščancev pred boleznijo Newcastle in Marekovo boleznijo.
Vectormune ND is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription.
Zdravilo Vectormune ND je na voljo v obliki suspenzije in vehikla za pripravo suspenzije za injiciranje in se izdaja le na recept.
Vectormune ND suspension and solvent for suspension for injection for chickens
Vectormune ND suspenzija in topilo za suspenzijo za injiciranje za piščance
Vectra 3D for dogs 1.5–4 kg
Vectra 3D za pse 1.5–4 kg
Vectra 3D for dogs 10–25 kg
Vectra 3D za pse 10–25 kg
Vectra 3D for dogs 25–40 kg
Vectra 3D za pse 25–40 kg
Vectra 3D for dogs 4–10 kg
Vectra 3D za pse 4–10 kg
Vectra 3D is a veterinary medicine that contains three active substances: dinotefuran, pyriproxyfen and permethrin.
Vectra 3D je zdravilo za uporabo v veterinarski medicini, ki vsebuje tri zdravilne učinkovine: dinotefuran, piriproksifen in permetrin.
Vectra 3D is used on dogs to treat and prevent flea and tick infestations and to repel sand flies, mosquitoes and stable flies.
Zdravilo Vectra 3D se uporablja za zdravljenje in preprečevanje infestacij z bolhami in klopi ter za odganjanje peščenih muh, komarjev in hlevskih muh pri psih.
Vectra 3D should not enter water courses as it is dangerous for fish and other aquatic organisms.
Vectra 3D ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Vectra 3D spot-on (1.5–4 kg) Vectra 3D spot-on (4–10 kg) Vectra 3D spot-on (10–25 kg) Vectra 3D spot-on (25–40 kg) Vectra 3D spot-on (> 40 kg)
Vectra 3D kožni nanos (1.5–4 kg) Vectra 3D kožni nanos (4–10 kg) Vectra 3D kožni nanos (10–25 kg) Vectra 3D kožni nanos (25–40 kg) Vectra 3D kožni nanos (> 40 kg)
Vectra 3D spot-on solution for dogs 1.5–4 kg Vectra 3D spot-on solution for dogs 4–10 kg Vectra 3D spot-on solution for dogs 10–25 kg Vectra 3D spot-on solution for dogs 25–40 kg Vectra 3D spot-on solution for dogs > 40 kg
Vectra 3D kožni nanos, raztopina za pse 1.5–4 kg Vectra 3D kožni nanos, raztopina za pse 4–10 kg Vectra 3D kožni nanos, raztopina za pse 10–25 kg Vectra 3D kožni nanos, raztopina za pse 25–40 kg Vectra 3D kožni nanos, raztopina za pse > 40 kg
Vectra Felis 423 mg/42.3 mg spot-on solution for cats
Vectra Felis 423 mg/42,3 mg kožni nanos, raztopina za mačke
Vectra Felis 423 mg/42.3 mg spot-on solution for cats dinotefuran/pyriproxyfen
Vectra Felis 423 mg/42,3 mg kožni nanos, raztopina za mačke dinotefuran/piriproksifen
Vectra Felis is a veterinary medicine that contains two active substances: dinotefuran and pyriproxyfen.
Vectra Felis je zdravilo za uporabo v veterinarski medicini, ki vsebuje dve zdravilni učinkovini: dinotefuran in piriproksifen.
Vectra Felis is used on cats to treat and prevent flea infestations.
Zdravilo Vectra Felis se uporablja za zdravljenje in preprečevanje bolhavosti pri mačkah.
Vectra Felis should not be disposed of via wastewater or household waste.
Ne odvrzite vectra Felis v odpadno vodo ali v gospodinjske odpadke.
Vectra Felis should not enter water courses as it is dangerous for fish and other aquatic organisms.
Vectra Felis ne sme priti v površinske vode, ker je škodljivo za ribe in druge vodne organizme.
Vectra Felis should not enter water courses as it is dangerous for fish and other aquatic organisms.
Vectra Felis ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Vectra Felis spot-on
Vectra Felis kožni nanos
Vedaprofen blocks an enzyme (cyclo-oxygenase) that is involved in the production of prostaglandins.
Vedaprofen zavira encim (ciklooksigenazo), ki sodeluje pri tvorbi prostaglandinov.
Vedolizumab blocks a protein on the surface of white blood cells that cause the inflammation in ulcerative colitis and Crohn’s disease, and so the amount of inflammation is reduced.
Vedolizumab blokira beljakovino na površini belih krvnih celic, ki povzročajo vnetje pri ulceroznem kolitisu in Crohnovi bolezni, in posledično zmanjša vnetje.
Vedolizumab Every 4 Weeks
Vedolizumab vsake 4 tedne
Vedolizumab Every 8 Weeks
Vedolizumab vsakih 8 tednov
Vedolizumab exhibited linear pharmacokinetics at serum concentrations greater than 1 mcg/ml.
Vedolizumab pri koncentracijah v serumu, večjih od 1 μg/ml, kaže linearno farmakokinetiko.
Vedolizumab has been designed to attach to ‘alfa-4-beta-7 integrin’, a protein mostly found on the surface of certain white blood cells in the gut.
Vedolizumab je bil zasnovan tako, da se veže na „integrin alfa-4- beta-7“, beljakovino, ki je najpogosteje prisotna na površini določenih belih krvnih celic v črevesju.
Vedolizumab has been studied in adult ulcerative colitis and Crohn’s disease patients with concomitant administration of corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), and aminosalicylates.
Uporabo vedolizumaba so raziskovali pri odraslih bolnikih z ulceroznim kolitisom in Crohnovo boleznijo, ki so sočasno uporabljali kortikosteroide, imunomodulatorje (azatioprin, 6-merkaptopurin in metotreksat) ter aminosalicilate.
Vedolizumab has been studied in three placebo-controlled clinical trials in patients with ulcerative colitis (GEMINI I) or Crohn’s disease (GEMINI II and III).
Vedolizumab so proučevali v treh s placebom nadzorovanih kliničnih preskušanjih pri bolnikih z ulceroznim kolitisom (GEMINI I) ali s Crohnovo boleznijo (GEMINI II in III).
Vedolizumab is a humanised IgG1 monoclonal antibody that binds to the human α4β7 integrin and is produced in Chinese hamster ovary (CHO) cells.
Vedolizumab je humanizirano IgG1 monoklonsko protitelo, ki se veže na humani integrin α4β7, pridobljeno na ovarijskih celicah kitajskega hrčka (celice CHO; “Chinese hamster ovary”).
Vedolizumab reduces gastrointestinal inflammation in UC patients.
Pri bolnikih z ulceroznim kolitisom vedolizumab zmanjša gastrointestinalno vnetje.
Vedolizumab should be administered in a healthcare setting equipped to allow management of acute hypersensitivity reactions including anaphylaxis, if they occur.
Vedolizumab je treba uporabljati v ustrezno opremljenih zdravstvenih ustanovah, kjer je v primeru pojava akutnih preobčutljivostnih reakcij, vključno z anafilaksijo, mogoče nemudoma uvesti ustrezne ukrepe.
Vedrop 50 mg/ml oral solution
Vedrop 50 mg/ml peroralna raztopina
Vedrop contains 0.18 mmoles (4.1 mg) sodium per ml.
Zdravilo Vedrop vsebuje 0,18 mmolov (4,1 mg) natrija na ml.
Vedrop contains sodium methyl parahydroxybenzoate (E219) and sodium ethyl parahydroxybenzoate (E215), which may cause allergic reactions (possibly delayed).
Zdravilo Vedrop vsebuje natrijev metilparahidroksibenzoat (E219) in natrijev etilparahidroksibenzoat (E215), ki lahko povzročita alergijske reakcije (lahko zapoznele).
Vedrop has been authorised under ‘Exceptional Circumstances’.
Zdravilo Vedrop je bilo odobreno „v izjemnih okoliščinah“.
Vedrop is a slightly viscous pale yellow oral solution in a brown glass bottle.
Zdravilo Vedrop je rahlo viskozna rumena peroralna raztopina v rjavi steklenici.
Vedrop is an oral solution that contains the active substance tocofersolan.
Zdravilo Vedrop je peroralna raztopina, ki vsebuje zdravilno učinkovino tokofersolan.
Vedrop is given by mouth, with or without water.
Zdravilo Vedrop se zaužije peroralno, z vodo ali brez nje.
Vedrop is not likely to affect your ability to drive and use machines.
Ni verjetno, da bi zdravilo Vedrop vplivalo na sposobnost vožnje in upravljanja s stroji.
Vedrop is used to treat or prevent vitamin E deficiency (low vitamin E levels).
Zdravilo Vedrop se uporablja za preprečevanje pomanjkanja vitamina E (nizkih ravni vitamina E).
Vedrop must not be used in newborn premature babies.
Zdravila Vedrop ne smete uporabljati pri nedonošenih novorojenčkih.
Vedrop should not be used in people who may be hypersensitive (allergic) to tocofersolan or any of the other ingredients.
Zdravila Vedrop ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) tokofersolan ali katero koli drugo sestavino zdravila.
VEG108844 achieved its primary endpoint of PFS and demonstrated that pazopanib was non-inferior to sunitinib, as the upper bound of the 95 % CI for the hazard ratio was less than the protocol-specified non- inferiority margin of 1.25. Overall efficacy results are summarised in Table 5.
Študija VEG108844 je dosegla primarni opazovani dogodek preživetja brez napredovanja in je pokazala, da je pazopanib neinferioren sunitinibu, ker je bila zgornja meja 95 % IZ za razmerje ogroženosti manjša od v protokolu opredeljene meje neinferiornosti 1,25.
VEGF-A and PlGF are involved in stimulating the abnormal growth of blood vessels in patients with AMD, certain types of macular oedema and myopic choroidal neovascularisation.
VEGF-A in PIGF sodelujeta pri spodbujanju nenormalne rasti krvnih žil pri bolnikih s starostno degeneracijo makule, določenih vrst makularnih edemom in horoidalne neovaskularizacije, ki jo povzroča kratkovidnost.
VEGF-A is a protein that makes blood vessels grow and leak fluid and blood.
VEGF-A je beljakovina, ki omogoča rast krvnih žil ter prepuščanje tekočine in krvi.
VEGF-D, sVEGFR1, sVEGFR2 and sVEGFR3 from plasma, VEGFR2 IHC will be submitted by
VEGF-D, sVEGFR1, sVEGFR2 in sVEGFR3 iz plazme, VEGFR2 IHC bo predložena
VEGF-D, sVEGFR1, sVEGFR2 and sVEGFR3 from plasma, VEGFR2 IHC, additional KRAS, NRAS and BRAF mutations) and efficacy outcome (PFS, OS), the MAH should submit the results of a biomarker assay from the RAISE translational research population.
dodatno KRAS, NRAS in BRAF mutacij) in učinkovitostjo (PFS, OS), mora imetnik dovoljenja za promet predložiti rezultate testov biomarkerjev raziskovalne populacije v študiji RAISE.
Vehicle
Vehikel
Vehicle (n=232)
Vehikel (n = 232)
Vehicle (n=270 )
Vehikel (n = 270)
Vehicle Gel n=63
Gel z vehiklom n=63
Vehicle Twice weekly (N=73)
Vehikel dvakrat na teden (n = 73)
Vehicle Twice weekly (N=75)
Vehikel dvakrat na teden (n = 75)
vein discolouration, pale skin
prememba barve ven, bleda koža,
Vein disorder
bolezni ven
vein inflammation
vnetje ven
vein inflammation
vnetje ven,
vein irritation
draženje ven,
Vein irritations from the injection, including pain, inflammation, swelling and clotting
draženje vene zaradi injiciranja, ki vključuje bolečino, vnetje, oteklino in krvni strdek
Vein thrombosis
venska tromboza
vein thrombosis) (see
(glejte
vein thrombosis) (see
vensko trombozo)
Vein wall inflammation where the intravenous infusion (or “drip”) goes into your vein (phlebitis)
vnetje stene vene na mestu infundiranja zdravila v vašo veno (flebitis)
Velactis 1.12 mg/ml solution for injection cabergoline
Velactis 1,12 mg/ml raztopina za injiciranje kabergolin
Velactis 1.12 mg/ml solution for injection for cattle
Velactis 1,12 mg/ml raztopina za injiciranje za govedo
Velactis 1.12 mg/ml solution for injection for cattle (dairy cows). cabergoline
Velactis 1,12 mg/ml raztopina za injiciranje za govedo (krave molznice). kabergolin
Velactis 1.12 mg/ml solution for injection for cattle.
Velactis 1,12 mg/ml raztopina za injiciranje za govedo
Velactis 1.12 mg/ml solution for injection for cattle. cabergoline
Velactis 1,12 mg/ml raztopina za injiciranje za govedo kabergolin
Velactis is available as a solution for injection in multidose vials of 5 ml, 25 ml or 50 ml.
Zdravilo Velactis je na voljo kot raztopina za injiciranje v večodmernih vialah s 5 ml, 25 ml ali 50 ml.
Velactis is given as a single injection into the muscle within four hours of the last milking on the day of drying off.
Zdravilo Velactis se injicira v enem odmerku v mišico v 4 urah po zadnji molži na dan presušitve.
Velactis should be used as part of a comprehensive mastitis and milk quality control program under veterinarian advice which might include the need to use intramammary treatment.
Velactis je potrebno uporabljati kot del celovitega programa za nadzor mastitisa in kakovosti mleka v skladu z navodili veterinarja, ki lahko vključujejo tudi uporabo intramamarnega zdravljenja.
velaglucerase alfa
velaglucerazo alfa
VELCADE 1 mg powder for solution for injection bortezomib
VELCADE 1 mg prašek za raztopino za injiciranje bortezomib
VELCADE 1 mg powder for solution for injection is administered via intravenous injection in combination with oral melphalan and oral prednisone as shown in Table 2.
Zdravilo VELCADE 1 mg prašek za raztopino za injiciranje se daje intravensko v kombinaciji s peroralnim melfalanom in prednizonom, kot je prikazano v preglednici 2.
VELCADE 1 mg powder for solution for injection is available for intravenous administration only.
Zdravilo VELCADE 1 mg prašek za raztopino za injiciranje je samo za intravensko uporabo.
VELCADE 1 mg powder for solution for injection is for intravenous administration only.
Zdravilo VELCADE 1 mg prašek za raztopino za injiciranje je namenjeno samo za intravensko uporabo.
VELCADE 1 mg powder for solution for injection IS FOR INTRAVENOUS USE ONLY.
Zdravilo VELCADE 1 mg prašek za raztopino za injiciranje je SAMO ZA INTRAVENSKO UPORABO.
VELCADE 3.5 mg powder for solution for injection bortezomib
VELCADE 3,5 mg prašek za raztopino za injiciranje bortezomib
VELCADE 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in Table 2.
Zdravilo VELCADE 3,5 mg se daje intravensko ali subkutano v kombinaciji s peroralnim melfalanom in prednizonom, kot je prikazano v preglednici 2.
VELCADE as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.
Zdravilo VELCADE je indicirano za zdravljenje napredujočega diseminiranega plazmocitoma v monoterapiji ali v kombinaciji s pegiliranim liposomskim doksorubicinom ali z deksametazonom pri odraslih bolnikih, ki so prejeli najmanj eno predhodno vrsto zdravljenja in so jim že presadili krvotvorne matične celice ali presaditev pri njih ni mogoča.
VELCADE combination treatment with dexamethasone
Zdravilo VELCADE v kombinaciji z deksametazonom
VELCADE contains the active substance bortezomib, a so-called ‘proteasome inhibitor’.
Zdravilo VELCADE vsebuje učinkovino bortezomib, ki je zaviralec proteasomov.
VELCADE dose should be reduced by 1 dose level (from 1.3 mg/m2 to 1 mg/m2, or from
Odmerek zdravila VELCADE je treba zmanjšati za 1 stopnjo (z 1,3 mg/m2 na 1 mg/m2 ali z
VELCADE is given intravenously on days 1, 4, 8 and 11, followed by a ‘rest period’ without treatment.
Zdravilo VELCADE boste prejeli intravensko na 1., 4., 8. in 11. dan, temu pa bo sledil premor brez zdravljenja.
VELCADE is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a ‘rest period’ without treatment.
Zdravilo VELCADE boste prejeli v veno ali v podkožje na 1., 4., 8. in 11. dan, temu pa bo sledil premor brez zdravljenja.
VELCADE is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years:
Zdravilo VELCADE se uporablja za zdravljenje diseminiranega plazmocitoma (rak kostnega mozga) pri bolnikih, starejših od 18 let:
VELCADE might cause tiredness, dizziness, fainting, or blurred vision.
Zdravilo VELCADE lahko povzroči utrujenost, omotičnost, omedlevico ali zamegljen vid.
VELCADE powder for solution for injection is a white to off-white cake or powder.
VELCADE prašek za raztopino za injiciranje je bela do belkasta pogača ali prašek.
VELCADE should not be administered intrathecally.
Zdravila VELCADE ne smete dajati intratekalno.
VELCADE therapy should be withheld
Zdravljenje z zdravilom VELCADE prekinite.
VELCADE therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better.
Zdravljenje z zdravilom VELCADE je treba prekiniti dokler se simptomi toksičnosti ne povrnejo na 2. stopnjo ali še izboljšajo.
VELCADE treatment is very commonly associated with haematological toxicities (thrombocytopenia, neutropenia and anaemia).
Zdravljenje z zdravilom VELCADE je zelo pogosto povezano s toksičnimi učinki ne hematološki sistem (trombocitopenija, nevtropenija in anemija).
Velcade was originally authorised under ‘exceptional circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Zdravilo Velcade je prvotno pridobilo dovoljenje za promet v „izjemnih okoliščinah“, saj so bile zaradi znanstvenih razlogov ob odobritvi na voljo le omejene informacije.
VELCADE will be administered by a health care professional experienced in the use of cytotoxic medicines.
Zdravilo VELCADE vam bo injiciral zdravstveni delavec z izkušnjami z uporabo citotoksičnih zdravil.
Velmetia has no or negligible influence on the ability to drive and use machines.
Zdravilo Velmetia nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Velmetia is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.
Zdravilo Velmetia je indicirano za trojno kombinirano zdravljenje z agonistom receptorja gama, aktiviranega s peroksisomskim proliferatorjem (PPAR – peroxisome proliferator-activated receptor gamma) (tj. s tiazolidindionom) kot dodatek dieti in telesni aktivnosti pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka metformina, ki ga prenašajo, in agonista PPAR.
Velmetia must not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Zdravila Velmetia se pri bolnikih z okvaro jeter ne sme uporabljati (glejte poglavji 4.3 in 5.2).